Annovis Bio, Inc. has completed the transfer of its patent rights to fully encompass both the original semi-crystalline and the new crystalline forms of its drug candidate buntanetap, according to the company.
The updated intellectual property portfolio now spans 13 patent families with international filings, providing comprehensive protection for both formulations and extending until 2046.
Annovis identified a crystalline form of buntanetap that offers enhanced solid-state stability while maintaining comparable pharmacokinetic characteristics to the original version. Animal and human studies have confirmed bioequivalence with identical systemic exposure.
These findings were presented at the Alzheimer’s Association International Conference (AAIC) 2025 in Toronto.
The patent update complements FDA approval of the crystalline form for use in the company’s ongoing Phase 3 clinical trial in early Alzheimer’s disease. The trial began earlier this year, involves over 75 sites in the U.S., and continues to enroll participants.
This development bolsters Annovis’s IP position and supports the continued clinical advancement of buntanetap across both formulations.
